Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Conformed diagnosis of follicular lymphoma, grades 1,2 or 3~* No prior chemotherapy~* No prior monoclonal antibody therapy~* Bulky or symptomatic disease, stage II-IV~* Performance status 0-2~Exclusion Criteria:~* Impaired bone marrow reserve~* Presence of CNS lymphoma~* Serious nonmalignant disease or active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).